The role of CD44 in epithelial–mesenchymal transition and cancer development

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 3783-3792

  Xu, Hanxiao ^a   Tian, Yijun ^a   Yuan, Xun ^a   Wu, Hua ^a   Liu, Qian ^a   Pestell, Richard G ^b   Wu, Kongming ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

CD44; Epithelial mesenchymal transition; Prognosis; Tumor progression

Indexed keywords

CD44 MONOCLONAL ANTIBODY; CD44V ANTIGEN; CD44V9 ANTIGEN; DOXORUBICIN; GEMCITABINE; HERMES ANTIGEN; MICRORNA; MONOCLONAL ANTIBODY; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG;

ABLATION THERAPY; ANTIGEN EXPRESSION; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CD44 GENE; CELL ADHESION; CELL RENEWAL; COLON CANCER; DISEASE FREE SURVIVAL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FOXP3 GENE; GENE; GLIOMA; HORMONAL THERAPY; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOUTH CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHENOTYPE; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SLUG GENE; SNAIL GENE; STOMACH CANCER; TRANSCRIPTION REGULATION; TUMOR INVASION; TWIST1 GENE; UPREGULATION; ZEB1 GENE;

EID: 84949982731     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S95470     Document Type: Review

References (94)

1. Spring FA, Dalchau R, Daniels GL, et al. The Ina and Inb blood group antigens are located on a glycoprotein of 80, 000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene. Immunology. 1988; 64(1): 37-43.
2. Rodrigo JP, Dominguez F, Alvarez C, Gonzalez MV, Herrero A, Suarez C. Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx. Am J Clin Pathol. 2002; 118(1): 67-72.
3. Erb U, Megaptche AP, Gu X, Buchler MW, Zoller M. CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells. J Hematol Oncol. 2014; 7: 29.
4. Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front Immunol. 2015; 6: 201.
5. Misra S, Heldin P, Hascall VC, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011; 278(9): 1429-1443.
6. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003; 4(1): 33-45.
7. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem. 2002; 277(7): 4589-4592.
8. Misra S, Hascall VC, De Giovanni C, Markwald RR, Ghatak S. Delivery of CD44shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J Biol Chem. 2009; 284(18): 12432-12446.
9. van der Windt GJ, Schouten M, Zeerleder S, Florquin S, van der Poll T. CD44 is protective during hyperoxia-induced lung injury. Am J Respir Cell Mol Biol. 2011; 44(3): 377-383.
10. Chanmee T, Ontong P, Kimata K, Itano N. Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells. Front Oncol. 2015; 5: 180.
11. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997; 71: 241-319.
12. Jang BI, Li Y, Graham DY, Cen P. The role of CD44 in the pathogenesis, diagnosis, and therapy of gastric cancer. Gut Liver. 2011; 5(4): 397-405.
13. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004; 95(12): 930-935.
14. Kwong LN, Dove WF. APC and its modifiers in colon cancer. Adv Exp Med Biol. 2009; 656: 85-106.
15. Wu K, Ning Z, Zeng J, et al. Silibinin inhibits beta-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal. 2013; 25(12): 2625-2633.
16. Uchino M, Kojima H, Wada K, et al. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells. BMC Cancer. 2010; 10: 414.
17. Yu G, Yao W, Xiao W, Li H, Xu H, Lang B. MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. J Exp Clin Cancer Res. 2014; 33: 779.
18. Xie G, Yao Q, Liu Y, et al. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int J Oncol. 2012; 40(4): 1171-1179.
19. Ross JS, Sheehan CE, Williams SS, Malfetano JH, Szyfelbein WM, Kallakury BV. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. Am J Clin Pathol. 2001; 116(1): 122-128.
20. Leung EL, Fiscus RR, Tung JW, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 2010; 5(11): e14062.
21. Brown RL, Reinke LM, Damerow MS, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011; 121(3): 1064-1074.
22. Shang Z, Cai Q, Zhang M, et al. A switch from CD44(+) cell to EMT cell drives the metastasis of prostate cancer. Oncotarget. 2015; 6(2): 1202-1216.
23. Xu GF, Zhang WJ, Sun Q, Xu X, Zou X, Guan W. Combined epithelial-mesenchymal transition with cancer stem cell-like marker as predictors of recurrence after radical resection for gastric cancer. World J Surg Oncol. 2014; 12: 368.
24. Su YJ, Lai HM, Chang YW, Chen GY, Lee JL. Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J. 2011; 30(15): 3186-3199.
25. Mahabir R, Tanino M, Elmansuri A, et al. Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro Oncol. 2014; 16(5): 671-685.
26. Chung SS, Aroh C, Vadgama JV. Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PLoS One. 2013; 8(12): e83971.
27. Kinugasa H, Whelan KA, Tanaka K, et al. Mitochondrial SOD2 regulates epithelial-mesenchymal transition and cell populations defined by differential CD44 expression. Oncogene. 2015; 34(41): 5229-5239.
28. Fernando J, Malfettone A, Cepeda EB, et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer. 2015; 136(4): E161-E172.
29. Song Y, Li J, Zhu Y, et al. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget. 2014; 5(22): 11669-11680.
30. Tian L, Li M, Ge J, et al. MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. Tumour Biol. 2014; 35(6): 5953-5963.
31. Wang PC, Weng CC, Hou YS, et al. Activation of VCAM-1 and its associated molecule CD44 leads to increased malignant potential of breast cancer cells. Int J Mol Sci. 2014; 15(3): 3560-3579.
32. Xing P, Li JG, Jin F, et al. Fascin, an actin-bundling protein, promotes breast cancer progression in vitro. Cell Biochem Funct. 2011; 29(4): 303-310.
33. Li L, Liu C, Amato RJ, Chang JT, Du G, Li W. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. Oncotarget. 2014; 5(21): 10840-10853.
34. Li J, Zhou BP. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 2011; 11: 49.
35. Yu M, Smolen GA, Zhang J, et al. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev. 2009; 23(15): 1737-1742.
36. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4): 704-715.
37. Fang X, Cai Y, Liu J, et al. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene. 2011; 30(47): 4707-4720.
38. Lee JK, Joo KM, Lee J, Yoon Y, Nam DH. Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling. Onco Targets Ther. 2014; 7: 1933-1944.
39. Zhang Z, Filho MS, Nor JE. The biology of head and neck cancer stem cells. Oral Oncol. 2012; 48(1): 1-9.
40. Way TD, Huang JT, Chou CH, Huang CH, Yang MH, Ho CT. Emodin represses TWIST1-induced epithelial-mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the beta-catenin and Akt pathways. Eur J Cancer. 2014; 50(2): 366-378.
41. Masui T, Ota I, Yook JI, et al. Snail-induced epithelial-mesenchymal transition promotes cancer stem cell-like phenotype in head and neck cancer cells. Int J Oncol. 2014; 44(3): 693-699.
42. Deep G, Jain AK, Ramteke A, et al. SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin. Mol Cancer. 2014; 13: 37.
43. Marin-Aguilera M, Codony-Servat J, Reig O, et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther. 2014; 13(5): 1270-1284.
44. Bhat-Nakshatri P, Appaiah H, Ballas C, et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24-phenotype. BMC Cancer. 2010; 10: 411.
45. Ju SY, Chiou SH, Su Y. Maintenance of the stemness in CD44(+) HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression. Stem Cell Res. 2014; 12(1): 86-100.
46. Cho SH, Park YS, Kim HJ, et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol. 2012; 41(1): 211-218.
47. Yu D, Shin HS, Lee YS, Lee YC. miR-106b modulates cancer stem cell characteristics through TGF-beta/Smad signaling in CD44-positive gastric cancer cells. Lab Invest. 2014; 94(12): 1370-1381.
48. Wang L, Yang H, Abel EV, et al. ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis. Genes Dev. 2015; 29(2): 171-183.
49. Wang D, Zhu H, Liu Y, et al. The low chamber pancreatic cancer cells had stem-like characteristics in modified transwell system: is it a novel method to identify and enrich cancer stem-like cells? Biomed Res Int. 2014; 2014: 760303.
50. Jiang W, Zhang Y, Kane KT, et al. CD44 regulates pancreatic cancer invasion through MT1-MMP. Mol Cancer Res. 2015; 13(1): 9-15.
51. Nevo I, Woolard K, Cam M, et al. Identification of molecular pathways facilitating glioma cell invasion in situ. PLoS One. 2014; 9(11): e111783.
52. Mima K, Hayashi H, Imai K, et al. High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Sci. 2013; 20(4): 429-434.
53. Reinke LM, Xu Y, Cheng C. Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition. J Biol Chem. 2012; 287(43): 36435-36442.
54. Saito S, Okabe H, Watanabe M, et al. CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep. 2013; 29(4): 1570-1578.
55. Geng S, Guo Y, Wang Q, Li L, Wang J. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma. Arch Dermatol Res. 2013; 305(1): 35-47.
56. Zhang Y, Wei J, Wang H, et al. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer. Oncol Rep. 2012; 27(5): 1599-1605.
57. Liu S, Cong Y, Wang D, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2013; 2(1): 78-91.
58. Leontovich AA, Zhang S, Quatraro C, et al. Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. Int J Oncol. 2012; 40(6): 1858-1864.
59. Arif K, Hussain I, Rea C, El-Sheemy M. The role of Nanog expression in tamoxifen-resistant breast cancer cells. Onco Targets Ther. 2015; 8: 1327-1234.
60. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007; 104(24): 10158-10163.
61. Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008; 14(21): 6751-6760.
62. Santoyo-Ramos P, Likhatcheva M, Garcia-Zepeda EA, Castaneda-Patlan MC, Robles-Flores M. Hypoxia-inducible factors modulate the stemness and malignancy of colon cancer cells by playing opposite roles in canonical Wnt signaling. PLoS One. 2014; 9(11): e112580.
63. Masaki T, Goto A, Sugiyama M, et al. Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma. Cancer. 2001; 92(10): 2539-2546.
64. Lau WM, Teng E, Chong HS, et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 2014; 74(9): 2630-2641.
65. Wang D, Lu P, Zhang H, et al. Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget. 2014; 5(21): 10803-10815.
66. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009; 106(33): 13820-13825.
67. Kondo S, Wakisaka N, Muramatsu M, et al. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J Virol. 2011; 85(21): 11255-11264.
68. McFarlane S, McFarlane C, Montgomery N, Hill A, Waugh DJ. CD44-mediated activation of alpha5beta1-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and Fibronectin-enriched matrices. Oncotarget. 2015; 6(34): 36762-36773.
69. Hanley WD, Burdick MM, Konstantopoulos K, Sackstein R. CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. Cancer Res. 2005; 65(13): 5812-5817.
70. Shirure VS, Liu T, Delgadillo LF, et al. CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions. Am J Physiol Cell Physiol. 2015; 308(1): C68-C78.
71. McFarlane S, Coulter JA, Tibbits P, et al. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget. 2015; 6(13): 11465-11476.
72. Kim Y, Kumar S. CD44-mediated adhesion to hyaluronic acid contributes to mechanosensing and invasive motility. Mol Cancer Res. 2014; 12(10): 1416-1429.
73. Perrot G, Langlois B, Devy J, et al. LRP-1-CD44, a new cell surface complex regulating tumor cell adhesion. Mol Cell Biol. 2012; 32(16): 3293-3307.
74. Zhang C, Xu Y, Hao Q, et al. FOXP3 suppresses breast cancer metastasis through downregulation of CD44. Int J Cancer. 2015; 137(6): 1279-1290.
75. Paulis YW, Huijbers EJ, van der Schaft DW, et al. CD44 enhances tumor aggressiveness by promoting tumor cell plasticity. Oncotarget. 2015; 6(23): 19634-19646.
76. Fang XJ, Xu WL, Gong JL, Chen C, Fang LL, Chen QY. CD44 variant increases the invasive ability of human breast cancer cell line MCF-7 cells. Zhonghua Zhong Liu Za Zhi. 2010; 32(1): 22-28.
77. Herrera-Gayol A, Jothy S. CD44 modulates Hs578T human breast cancer cell adhesion, migration, and invasiveness. Exp Mol Pathol. 1999; 66(1): 99-108.
78. Nam K, Oh S, Lee KM, Yoo SA, Shin I. CD44 regulates cell proliferation, migration, and invasion via modulation of c-Src transcription in human breast cancer cells. Cell Signal. 2015; 27(9): 1882-1894.
79. Montgomery N, Hill A, McFarlane S, et al. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res. 2012; 14(3): R84.
80. Klarmann GJ, Hurt EM, Mathews LA, et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis. 2009; 26(5): 433-446.
81. Gao Y, Foster R, Yang X, et al. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget. 2015; 6(11): 9313-9326.
82. Martin-Villar E, Fernandez-Munoz B, Parsons M, et al. Podoplanin associates with CD44 to promote directional cell migration. Mol Biol Cell. 2010; 21(24): 4387-4399.
83. Mikami S, Mizuno R, Kosaka T, Saya H, Oya M, Okada Y. Expression of TNF-alpha and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer. 2015; 136(7): 1504-1514.
84. Nicolini A, Ferrari P, Fini M, et al. Stem cells: their role in breast cancer development and resistance to treatment. Curr Pharm Biotechnol. 2011; 12(2): 196-205.
85. Wei X, Xu M, Wei Y, et al. The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression. J Hematol Oncol. 2014; 7: 34.
86. Ni J, Cozzi PJ, Hao JL, et al. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate. 2014; 74(6): 602-617.
87. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemia stem cells. Nat Med. 2006; 12(10): 1167-1174.
88. Dan T, Hewitt SM, Ohri N, et al. CD44 is prognostic for overall survival in the NCI randomized trial on breast conservation with 25 year follow-up. Breast Cancer Res Treat. 2014; 143(1): 11-18.
89. Wu XJ, Li XD, Zhang H, et al. Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer. J Int Med Res. 2015; 43(2): 173-179.
90. Go SI, Ko GH, Lee WS, et al. CD44 variant 9 serves as a poor prognostic marker in early gastric cancer, but not in advanced gastric cancer. Cancer Res Treat. Epub 2015 Mar 17.
91. Ahmed MA, Aleskandarany MA, Rakha EA, et al. A CD44(-)/CD24(+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat. 2012; 133(3): 979-995.
92. Basakran NS. CD44 as a potential diagnostic tumor marker. Saudi Med J. 2015; 36(3): 273-279.
93. Jiang L, Deng J, Zhu X, et al. CD44 rs13347 C. T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Res. 2012; 14(4): R105.
94. Lu X, Xu K, Lu H, et al. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas. Ultrastruct Pathol. 2011; 35(2): 72-78.